Jonathan Phillips

Dr. Jonathan Phillips

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Sensors
Verified
Journal Article
Open access
PDF file
SPSeon Cheol Park
Seon Cheol Park
Narongkorn SaiphoklangNarongkorn Saiphoklang
Narongkorn Saiphoklang
DJDonghyun Jung
Donghyun Jung
DGDavid Gomez Ladron de Guevara
David Gomez Ladron de Guevara
JPJonathan Phillips
Jonathan Phillips
CCChristopher B Cooper
Christopher B Cooper
The purpose of this study was to explore the relationships between heart rate variability (HRV) and various phenotypic measures that relate to health and functional status in chronic obstructive pulmonary disease (COPD), and secondly, to demonstrate the feasibility of ascertaining HRV via a chest-worn wearable biosensor in COPD patients. HRV analysis was performed using SDNN (standard deviation of the mean of all normal R-R intervals), low frequency (LF), high frequency (HF), and LF/HF ratio. We evaluated the associations between HRV and COPD severity, class of bronchodilator therapy prescribed, and patient reported outcomes. Seventy-nine participants with COPD were enrolled. There were no differences in SDNN, HF, and LF/HF ratio according to COPD severity. The SDNN in participants treated with concurrent beta-agonists and muscarinic antagonists was lower than that in other participants after adjusting heart rate (beta coefficient −3.980, p = 0.019). The SDNN was positively correlated with Veterans Specific Activity Questionnaire (VSAQ) score (r = 0.308, p = 0.006) and handgrip strength (r = 0.285, p = 0.011), and negatively correlated with dyspnea by modified Medical Research Council (mMRC) questionnaire (r = −0.234, p = 0.039), health status by Saint George’s Respiratory Questionnaire (SGRQ) (r = −0.298, p = 0.008), symptoms by COPD Assessment Test (CAT) (r = −0.280, p = 0.012), and BODE index (r = −0.269, p = 0.020). When measured by a chest-worn wearable device, reduced HRV was observed in COPD participants receiving inhaled beta-sympathomimetic agonist and muscarinic antagonists. HRV was also correlated with various health status and performance measures.

1 September 2002 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
JPJonathan Phillips
Jonathan Phillips
JHJohn Hey
John Hey
MCMichel R. Corboz
Michel R. Corboz
Submucosal glands secrete macromolecules and liquid that are essential for normal airway function. To determine the mechanisms responsible for airway gland secretion and the interaction between gland secretion and epithelial ion transport, studies were performed in porcine tracheal epithelia by using the hillocks and Ussing techniques. No significant baseline gland fluid flux ( J G) was measured by the hillocks technique after 3 min, and the epithelia had an average potential difference of 7.5 ± 0.5 mV (lumen negative) with a short-circuit current of 73 ± 4 μA/cm2, as measured by the Ussing technique. The secretagogue methacholine induced concentration-dependent increases in J G after 3 min from 0.003 μl · min−1 · cm−2 at 0.1 μM to 0.41 ± 0.04 μl · min−1 · cm−2 at 1,000 μM, with a 0.9 ± 0.1 mV hyperpolarization of the epithelium at 1,000 μM. When the epithelium was pretreated for 3 min with the sodium channel blocker amiloride, the methacholine (1,000 μM)-induced J G increased to 0.67 ± 0.09 μl · min−1 · cm−2, and the hyperpolarization increased to 2.2 ± 0.5 mV over the amiloride-pretreated level. When pretreated for 3 min with the chloride channel blocker diphenylamine-2-carboxylic acid, the methacholine (1,000 μM)-induced J G was inhibited to 0.20 ± 0.06 μl · min−1 · cm−2, and the methacholine-induced hyperpolarization was abolished. These data indicate that, in porcine airways, methacholine-induced J G may be increased by inhibition of sodium absorption and decreased by inhibition of chloride secretion.

1 July 2023 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
SPSeon Cheol Park
Seon Cheol Park
Narongkorn SaiphoklangNarongkorn Saiphoklang
Narongkorn Saiphoklang
JPJonathan Phillips
Jonathan Phillips
MWMay-Lin Wilgus
May-Lin Wilgus
RBRussell Buhr
Russell Buhr
IBIgor Barjaktarevic
Igor Barjaktarevic
Introduction: Clinical decisions in chronic obstructive pulmonary disease (COPD) treatment often utilize serially assessed physiologic parameters and biomarkers. To better understand the reliability of these tests, we evaluated changes in commonly assessed biomarkers over 3 months in patients with clinically stable COPD. Methods: We performed an observational prospective cohort study of 89 individuals with clinically stable COPD, defined as no exacerbation history within 3 months of enrollment. Biomarkers included lung function and functional performance status, patient-reported outcomes of symptoms and health status, and blood markers of inflammation. The correlation between testing at baseline and at 3-month follow-up was reported as the intraclass correlation coefficient (ICC). “Outliers” had significant variability between tests, defined as > 1.645 standard deviations between the two measurements. Differences in clinical features between outliers and others were compared. Results: Participants with COPD (n = 89) were 70.5 ± 6.7 years old, 54 (61%) male, had a 40 pack-year smoking history with 24.7% being current smokers, and postbronchodilator forced expiratory volume in one second (FEV1) 62.3 ± 22.7% predicted. The biomarkers with excellent agreement between the initial and the follow-up measurements were FEV1 (ICC = 0.96), Saint George’s Respiratory Questionnaire (SGRQ) (ICC = 0.98), COPD Assessment Test (CAT) (ICC = 0.93) and C-reactive protein (CRP) (ICC = 0.90). By contrast, parameters showing less robust agreement were 6-minute walking distance (ICC = 0.75), eosinophil count (ICC = 0.77), erythrocyte sedimentation rate (ICC = 0.75) and white blood cell count (ICC = 0.48). Individuals with greater variability in biomarkers reported chronic bronchitis more often and had higher baseline SGRQ and CAT scores. Conclusion: Our study evaluated the stability of commonly assessed biomarkers in clinically stable COPD and showed excellent agreement between baseline and three-month follow-up values for FEV1, SGRQ, CAT and CRP. Individuals with chronic bronchitis and more symptomatic disease at baseline demonstrated greater variability in 3-month interval biomarkers.

1 May 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PBPurakkattle Biju
Purakkattle Biju
HWhongwu Wang
hongwu Wang
JAJohn Anthes
John Anthes
KMKevin McCormick
Kevin McCormick
RARobert Aslanian
Robert Aslanian
JPJonathan Phillips
Jonathan Phillips

8 July 2024 in Respiratory Medicine
Verified
Journal Article
Open access
MFMarisa Fat
Marisa Fat
TATyler Andersen
Tyler Andersen
JFJane C. Fazio
Jane C. Fazio
SPSeon Cheol Park
Seon Cheol Park
FAFereidoun Abtin
Fereidoun Abtin
IBIgor Barjaktarevic
Igor Barjaktarevic
Chronic Bronchitis (CB) represents a phenotype of chronic obstructive pulmonary disease (COPD). While several definitions have been used for diagnosis, the relationship between clinical definitions and radiologic assessment of bronchial disease (BD) has not been well studied. The aim of this study was to evaluate the relationship between three clinical definitions of CB and radiographic findings of BD in spirometry-defined COPD patients. A cross-sectional analysis was performed from a COPD phenotyping study. It was a prospective observational cohort. Participants had spirometry-defined COPD and available chest CT imaging. Comparison between CB definitions, Medical Research Council (CBMRC), St. George's Respiratory Questionnaire (CBSGRQ), COPD Assessment Test (CBCAT) and CT findings were performed using Cohen's Kappa, univariate and multivariate logistic regressions. Of 112 participants, 83 met inclusion criteria. Demographics included age of 70.1 ± 7.0 years old, predominantly male (59.0 %), 45.8 ± 30.8 pack-year history, 21.7 % actively smoking, and mean FEV1 61.5 ± 21.1 %. With MRC, SGRQ and CAT definitions, 22.9 %, 36.6 % and 28.0 % had CB, respectively. BD was more often present in CB compared to non-CB patients; however, it did not have a statistically significant relationship between any of the CB definitions. CBSGRQ had better agreement with radiographically assessed BD compared to the other two definitions. Identification of BD on CT was associated with the diagnoses of CB. However, agreement between imaging and definitions were not significant, suggesting radiologic findings of BD and criteria defining CB may not identify the same COPD phenotype. Research to standardize imaging and clinical methods is needed for more objective identification of COPD phenotypes.

27 January 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
KMKent Miner
Kent Miner
KLKatja Labitzke
Katja Labitzke
BLBenxian Liu
Benxian Liu
PWPaul Wang
Paul Wang
KHKathryn Henckels
Kathryn Henckels
JSJohn K. K. Sullivan
John K. K. Sullivan
There is an unmet need in severe asthma where approximately 40% of patients exhibit poor β-agonist responsiveness, suffer daily symptoms and show frequent exacerbations. Antagonists of the Ca 2+ -activated-Cl − channel, TMEM16A, offers a new mechanism to bronchodilate airways and block the multiple contractiles operating in severe disease. To identify TMEM16A antagonists we screened a library of ~580,000 compounds. The anthelmintics niclosamide, nitazoxanide and related compounds were identified as potent TMEM16A antagonists that blocked airway smooth muscle depolarization and contraction. To evaluate whether TMEM16A antagonists resist use- and inflammatory-desensitization pathways limiting β-agonist action, we tested their efficacy under harsh conditions using maximally contracted airways or airways pretreated with a cytokine cocktail. Stunningly, TMEM16A antagonists fully bronchodilated airways, while the β-agonist isoproterenol showed only partial effects. Thus, antagonists of TMEM16A and repositioning of niclosamide and nitazoxanide represent an important additional treatment for patients with severe asthma and COPD that is poorly controlled with existing therapies. It is of note that drug repurposing has also attracted wide interest in niclosamide and nitazoxanide as a new treatment for cancer and infectious disease. For the first time we identify TMEM16A as a molecular target for these drugs and thus provide fresh insights into their mechanism for the treatment of these disorders in addition to respiratory disease.